Torrent Pharmaceuticals Ltd. benchmarking: Performance to industry peers

Financial

	Torrent Pharma	Cipla	Dr. Reddy's Labs.
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	174.0 .	285.0 .	376.0 .
Number of ANDA's Approved By USFDA	132.0 .	230.0 .	301.0 .
Domestic Sales Growth - YoY	11.6 %	7.7 %	11.3 %
R&D as a % of Total Sales	4.0 %	7.8 %	7.3 %
Financials
5 yr Average ROE	21.66 %	13.53 %	15.68 %
5yr average Equity Multiplier	2.73	1.22	1.41
5yr Average Asset Turnover Ratio	0.64	0.77	0.74
5yr Avg Net Profit Margin	13.92 %	14.55 %	15.18 %
Price to Book	18.23	3.38	2.97
P/E	70.68	29.99	26.85
5yr Avg Cash Conversion Cycle	-145.98 Days	-6.65 Days	74.48 Days
Inventory Days	53.66 Days	57.59 Days	76.14 Days
Days Receivable	45.41 Days	52.05 Days	95.44 Days
Days Payable	270.49 Days	107.59 Days	102.6 Days
5yr Average Interest Coverage Ratio	8.01	68.84	35.66
5yr Avg ROCE	23.39 %	19.16 %	21.82 %
5yr Avg Operating Profit Margin	30.55 %	22.76 %	23.61 %
5 yr average Debt to Equity	0.85	0.02	0.12
5yr CAGR Net Profit	22.72 %	9.04 %	23.71 %
5yr Average Return on Assets	8.89 %	11.12 %	11.24 %
Shareholdings
Promoter Holding	68.31 %	29.21 %	26.63 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-2.94 %	-4.34 %	-0.07 %
Change in Mutual Fund Holding (3 Yrs)	-1.92 %	3.66 %	3.32 %

Business

	Torrent Pharma	Cipla	Dr. Reddy's Labs.
Product Wise Break-Up	Product Wise Break-Up Domestic Formulations 42.15 US Formulations 20.71 Germany 13.15 Brazil 8.98 Contract Manufacturing 6.15 New ventures 0 Pharmaceuticals 0 Proprietary Products 0 Global Generics 0 0 Others 8.86	Product Wise Break-Up Proprietary Products 0 Global Generics 0 Domestic Formulations 0 Germany 0 Pharmaceutical 94.65 0 Brazil 0 US Formulations 0 Contract Manufacturing 0 New ventures 5.35	Product Wise Break-Up Proprietary 0.31 Formulations 85.33 Domestic Formulations 0 Germany 0 Pharmaceuticals 0 Pharmaceutical 14.36 Brazil 0 US Formulations 0 Contract Manufacturing 0 New ventures 0
Location Wise Break-Up	Location Wise Break-Up India 64.69 Brazil 13.29 USA 11.57 Germany 9.73 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Russia 0 Others 0.72	Location Wise Break-Up Emerging Markets 0 Europe 12.0 Germany 0 SAGA 19.0 India 46.0 Brazil 0 Rest of the World 0 North America 22.0 Global API 1.0 USA 0 Russia 0	Location Wise Break-Up Emerging Markets 0 Europe 0 Germany 0 SAGA 0 India 17.36 Brazil 0 Rest of the World 0 North America 0 Global API 0 USA 48.56 Russia 7.99 Others 26.09
Acute vs Chronic	Acute vs Chronic Chronic 76.0 Acute 24.0 Sub - chronic 0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 25.0 Gastro Intestinal 17.0 CNS 15.0 VMN 11.0 Anti - Diabetes 10.0 Pain Management 7.0 Gynecology 2.0 Anti-Infective 2.0 Rest 2.0 Respiratory 0 Anti-Infective 0 Central Nervous System 0 Pain Management 0 Cardiovascular 0 Oncology 0 Gastrointestinal 0 Others 9.0	-	Therapeutic Area Break-Up Anti-Infective 6.48 Central Nervous System (CNS) 12.12 VMN 0 Gastro Intestinal 9.52 Anti - Diabetes 0 CNS 0 Pain Management 9.77 Cardiac Science 0 Rest 0 Cardiac Science 6.65 Oncology 27.53 Gastro Intestinal 0 Respiratory 7.04 Gynecology 0 Others 20.89
Asset Break-Up	Asset Break-Up India 94.39 USA 0.46 South Africa 0 United States 0 Switzerland 0 Others 5.15	Asset Break-Up India 49.7 Switzerland 0 South Africa 18.03 United States 0 USA 28.99 Others 3.28	Asset Break-Up India 80.24 Switzerland 8.45 South Africa 0 USA 2.37 USA 0 Others 8.94

Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

Financial

Business

SIGN UP FOR FREE